Javad Charostad

@ssu.ac.ir

Department of Microbiology, Shahid Sadoghi University of Medical Science, Yazd, Iran

Javad Charostad


               Download Compact PDF  
https://researchid.co/dr.charosrad

EDUCATION

phd in medical virology

RESEARCH INTERESTS

Molecular Virology, Anti-Viral Peptides
41

Scopus Publications

832

Scholar Citations

14

Scholar h-index

17

Scholar i10-index

Scopus Publications

  • An extensive overview on MicroRNAs and pandemic-prone viral diseases: The next frontier in predicting and mitigating pandemics
    Niloofar Farsiu, Javad Charostad, Fatemeh Khodadadpour Mahani, Yousof Mir, Mohammad Rezaei Zadeh Rukerd, Nazanin Zeinali Nezhad, Amirhossein Shahpar, Mohammad Pardeshenas, Mohsen Nakhaie
    Infection Genetics and Evolution, 2026
    MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play important roles in host-virus interactions. Increasing evidence indicates that viral infections can alter host miRNA expression profiles, influencing viral replication, immune responses, and disease severity. In this review, we summarize current knowledge on miRNA dysregulation in major pandemic-prone viral infections, including severe acute respiratory syndrome coronavirus (SARS-CoV), SARS-CoV-2, (middle east respiratory syndrome coronavirus) MERS-CoV, and influenza viruses. We also discuss how specific miRNAs may function as antiviral or proviral regulators by targeting viral genomes or key host signaling pathways involved in immune responses and inflammation. Particular attention is given to the potential role of circulating miRNAs as diagnostic or prognostic biomarkers, as well as the emerging concept of miRNA-based therapeutics. While numerous studies report associations between altered miRNA expression and infection outcomes, most findings are derived from relatively small and heterogeneous cohorts and require further validation. Consequently, many proposed miRNA applications remain at an exploratory stage. Nevertheless, advances in high-throughput sequencing, integrative omics approaches, and functional validation studies are expected to improve our understanding of miRNA-mediated regulatory networks during viral infections. These developments may ultimately support the development of host-response biomarkers and therapeutic strategies that contribute to improved surveillance and preparedness for future viral outbreaks.
  • From legacy to innovation: A comprehensive review of vaccine platforms against viral infections
    Niloofar Farsiu, Fatemeh Khodadadpour Mahani, Nasir Arefinia, Javad Charostad, Mohammad Pardeshenas, Habibollah Mirzaei, Mohsen Nakhaie, Pouya Hassandarvish, Sazaly AbuBakar
    Virus Research, 2026
    Viral infections continue to pose a substantial global health concern, resulting in extensive morbidity and mortality among various populations. Although conventional vaccinations have been pivotal in managing and eliminating certain viral infections, the introduction of new viruses and the resurgence of existing ones underscore the ongoing necessity for creative immunization techniques. This review offers an extensive examination of both conventional and novel vaccine platforms for preventing viral diseases. It analyzes traditional approaches such as inactivated and attenuated vaccines in conjunction with innovative technologies, including subunit, viral vector-based, DNA, mRNA, and virus-like particle (VLP) vaccines. Furthermore, novel strategies to enhance vaccination efficacy, including nanoparticle-based and plant-derived vaccines, are examined. Each platform is evaluated according to its mode of action, immunogenicity, safety, scalability, and adaptation to novel threats. Empirical instances, especially observations from the COVID-19 pandemic, are employed to underscore the achievements, obstacles, and pragmatic utilization of these tools. By reviewing the scientific foundations and developmental pathways of diverse vaccine strategies, this paper offers a more profound understanding of the evolving landscape of viral vaccine development. Finally, this review emphasizes the critical role of innovation in strengthening global readiness for current and future outbreaks.
  • Aptamer-Based Approaches for Influenza Virus Detection: A Systematic Review
    Javad Charostad, Zohreh‐al‐sadat Ghoreshi, Nasir Arefinia, Faranak Salajegheh, Niloofar Farsiu, Mohammad Rezaei Zadeh Rukerd, Mohsen Nakhaie
    Health Science Reports, 2026
    Background and Aims Influenza remains a globally prevalent respiratory infection that is challenging to diagnose accurately. This systematic review focuses on aptamer‐based tools for influenza virus detection, aiming to overcome the limitations of traditional diagnostic methods. Methods Following PRISMA guidelines, we identified relevant studies from official databases (PubMed, Web of Science, Scopus, Embase, Google Scholar) and grey literature sources. The search strategy utilized keywords related to aptamers, systematic evolution of ligands by exponential enrichment (SELEX) techniques, and influenza. The qualitative synthesis included 22 articles out of 1432 studies. Results Our analysis revealed diverse aptamer‐based techniques for influenza detection, including fluorescence resonance energy transfer (FRET)‐based aptasensors, electrochemical sensors, and surface‐enhanced raman scattering (SERS)‐based methods. SELEX was the predominant method for aptamer development, ensuring high specificity and adaptability to various influenza strains. Notably, FRET‐based methods demonstrated detection limits as low as 0.43 ng/mL, while electrochemical approaches exhibited high sensitivity with low detection limits in the picomolar range. The findings highlight the advantages of aptamers, including cost‐effectiveness, stability, and rapid synthesis, though challenges related to reproducibility and technological complexity remain. Conclusion Aptamer‐based tools offer promising alternatives to traditional diagnostics, especially for rapid and field‐deployable influenza detection. Their adaptability and potential for multiplex detection underscore their role in advancing public health diagnostics. Further research should focus on optimizing sensitivity and simplifying technological requirements for broader clinical applications.
  • Dengue Fever: Viral, Environmental, and Human Factors Driving Expansion and Pandemic Risk
    Mohsen Nakhaie, Amirhossein Shahpar, Mohammad Rezaei Zadeh Rukerd, Niloofar Farsiu, Javad Charostad, Davood Bashash, Nazanin Zeinali Nezhad, Mohammad Pardeshenas, Azadeh Haghi Navand, Hanieh Mirkamali, Keivan Zandi, Sazaly AbuBakar
    Reviews in Medical Virology, 2026
    Dengue fever (DF), caused by the dengue virus (DENV), is the fastest‐spreading mosquito‐borne viral disease globally and presents significant public health challenges. This comprehensive review explores the multifaceted factors influencing DENV expansion and control. We examine viral factors, including serotypes, sub‐genotypes, genetic mutations, recombination, and immune evasion mechanisms, and their role in enhancing dengue's adaptability and virulence. The influence of environmental factors, such as climate change, global warming, and unplanned urbanization on mosquito vector distribution, and the impact of natural disasters and human conflicts on population dynamics and transmission risks are discussed. Human factors, including global travel, migration, inadequate public health infrastructure, and the role of herd immunity from previous infections and cyclical outbreaks, are critically assessed. Additionally, emerging challenges like co‐infections, drug resistance, and the potential for pandemic outbreaks are considered. By synthesizing current knowledge across these dimensions, this review provides insights into dengue transmission complexities and identifies key intervention areas, aiming to enhance strategies for prevention, control, and preparedness in the face of evolving global health threats.
  • Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue
    Niloofar Farsiu, Keivan Zandi, Mohammad Rezaei Zadeh Rukerd, Javad Charostad, Davood Bashash, Somayeh Ghafari, Mohammad Pardeshenas, Mahsan Shahri, Hanieh Mirkamali, Pouya Hassandarvish, Mohsen Nakhaie, Sazaly AbuBakar
    American Journal of Tropical Medicine and Hygiene, 2025
    Dengue fever (DF), caused by dengue virus (DENV), is a major global health concern, potentially affecting more than 390 million people annually across more than 100 countries. Despite extensive research, significant challenges persist in both prevention and therapeutic approaches toward dengue. Preventive strategies are mainly focused on vector control through physical, biological, and chemical methods, as well as vaccination efforts in recent years. Existing vaccines, such as Dengvaxia ® (Sanofi Pasteur, Paris, France) and Qdenga ® (Takeda Pharmaceutical Company, Tokyo, Japan), have demonstrated some efficacy; however, limitations include a lack of efficacy against certain regional DENV strains and the potential for antibody-dependent enhancement (ADE), particularly in individuals without previous DENV exposure. Therapeutic monoclonal antibodies against DENV are potential treatment options, but they are hindered by rapid elimination and ADE risks. The absence of suitable animal models that replicate the symptoms of DF further complicates vaccine and therapeutic development. Emerging strategies, including messenger RNA vaccines and engineered antibodies, show promise but would still require thorough validation for efficacy and safety. To date, therapeutic approaches to DF are predominantly supportive, focusing on symptom management and complication prevention. Although antiviral drugs and immunotherapies are under investigation, none have exhibited clinical success. The intricate pathogenesis of DENV, involving complex virus–host interactions and immune responses, presents additional treatment challenges. In this review, the current challenges and advancements in DF prevention and treatment are examined, emphasizing the limits of existing vaccines and medicines while exploring novel approaches with potential for effectiveness in clinical settings.
  • Evaluating the Role of COVID-19 Vaccines in Patient Outcomes: Evidence From the Eighth Wave in Kerman, Iran
    Fateme Raisi Sarbijan, Niloofar Farsiu, Sara Shafieipour, Hamid Abousaidi, Reza Sinaei, Alireza Amirbeigi, Javad Charostad, Mohsen Nakhaie
    Infectious Diseases in Clinical Practice, 2025
    Background The recent SARS-CoV-2 pandemic posed a significant threat to human life. Vaccines played an unprecedented role in managing adverse outcomes, but the virus's ability to mutate and produce new variants posed ongoing challenges. This research aimed to examine the association between different types and numbers of doses of COVID-19 vaccinations and the clinical and demographic characteristics of patients. Methods This retrospective cross-sectional study was carried out on 161 COVID-19 patients hospitalized at Afzalipour Hospital in Kerman, Iran, during the eighth wave of the pandemic. Data on demographic features, symptoms, patient status, disease outcome, and vaccination history of patients were collected. Results Most patients (over 75%) had received 2 or 3 doses of the vaccine. Vaccination type and the number of doses showed significant differences based on patient gender (P = 0.048) and age group (P = 0.034), respectively. Shortness of breath showed significant differences based on the type of vaccine received (P = 0.0178). Fatigue substantially differed based on the number of vaccine doses (P = 0.03975). There were no significant differences in gastrointestinal symptoms, patient or disease status based on the number or type of vaccines, but lower death rates were observed in vaccinated patients. Additionally, while trends indicated better outcomes with a higher number of vaccine doses, there were no significant variations in blood oxygen saturation (SpO2) or respiratory rate based on the type or number of vaccine doses. Conclusions The findings highlight the role of vaccination in managing COVID-19 outcomes despite the reduction of vaccine efficacy against emerging variants.
  • Mpox and Viral Co-Infections: A Narrative Review
    Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Niloofar Farsiu, Davood Bashash, Fatemeh Khodadadpour Mahani, Nasir Arefinia, Javad Charostad, Mohammad Zarei, Farzane Behnezhad
    Health Science Reports, 2025
    Background and AimsMonkeypox (Mpox), caused by the monkeypox virus (MPXV), has emerged as a significant global public health concern, particularly following a substantial multi‐country outbreak in mid‐2022. The World Health Organization (WHO) reported 109,699 laboratory‐confirmed Mpox cases and 236 fatalities worldwide from January 1, 2022, to September 30, 2024. This narrative review aims to evaluate the co‐infections of Mpox with various viral agents and assess their implications for public health.MethodsWe conducted a comprehensive review of the literature regarding Mpox co‐infections with human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), hepatitis viruses (hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV)), and herpesviruses (including herpes simplex virus (HSV)‐1, HSV‐2, varicella‐zoster virus (VZV), and cytomegalovirus (CMV)).ResultsWe analyzed epidemiological trends, clinical manifestations, preventive measures, treatment guidelines, and advanced diagnostic methodologies. The review highlights the intricate dynamics of Mpox co‐infections and underscores the necessity for comprehensive diagnostic approaches, including viral load assays, to evaluate active co‐infections, particularly for HIV and HBV.ConclusionUnderstanding the interplay between MPXV and other viral pathogens is crucial for enhancing management strategies for co‐infections. By addressing these complexities, we aim to contribute valuable insights into the public health implications of Mpox co‐infections and improve response strategies.
  • Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications
    Mina Golban, Javad Charostad, Hossein Kazemian, Hamid Heidari
    Infectious Diseases and Therapy, 2025
    Antimicrobial resistance is a significant global public health issue, and the dissemination of antibiotic resistance in Gram-positive bacterial pathogens has significantly increased morbidity, mortality rates, and healthcare costs. Among them, Staphylococcus, especially methicillin-resistant Staphylococcus aureus (MRSA), causes a wide range of diseases due to its diverse pathogenic factors and infection strategies. These bacteria also present significant issues in veterinary medicine and food safety. Effectively managing staphylococci-related problems necessitates a concerted effort to implement preventive measures, rapidly detect the pathogen, and develop new and safe antimicrobial therapies. In recent years, there has been growing interest in using endolysins to combat bacterial infections. These enzymes, which are also referred to as lysins, are a unique class of hydrolytic enzymes synthesized by double-stranded DNA bacteriophages. They possess glycosidase, lytic transglycosylase, amidase, and endopeptidase activities, effectively destroying the peptidoglycan layer and resulting in bacterial lysis. This unique property makes endolysins powerful antimicrobial agents, particularly against Gram-positive organisms with more accessible peptidoglycan layers. Therefore, considering the potential benefits of endolysins compared to conventional antibiotics, we have endeavored to gather and review the characteristics and uses of endolysins derived from staphylococcal bacteriophages, as well as their antibacterial effectiveness against Staphylococcus spp. based on conducted experiments and trials.
  • Aptamer-based Strategies for COVID-19 Detection and Treatment: A Systematic Review Study
    Mohsen Nakhaie, Zohreh-al-sadat Ghoreshi, Javad Charostad, Faranak Salajegheh, Mohammad Rezaei Zadeh Rukerd, Nasir Arefinia
    Current Analytical Chemistry, 2025
    Background: Aptamer-based strategies have emerged as promising tools for the detection and treatment of COVID-19, offering advantages such as high specificity, sensitivity, and versatility. This systematic review aims to evaluate the effectiveness and innovation of aptamer-based approaches for COVID-19 detection and treatment. Methods: Following the guidelines of the Cochrane Handbook for Systematic Reviews and the PRISMA 2020 guidelines, a systematic search was conducted across multiple databases up to 2024. The search included studies that utilized aptamers for the diagnosis or therapy of COVID-19. Screening and selection of studies were performed independently by two reviewers, with any disagreements resolved by a third reviewer. Data were extracted regarding study characteristics, aptamer details, and outcomes. Results: In our systematic review, 98 studies from an initial pool of 1541 records met the inclusion criteria for analysis. Aptamers, single-stranded DNA or RNA molecules with unique threedimensional (3D) structures, were extensively explored for COVID-19 detection and treatment. Various aptamer-based assays, including electrochemical sensors, surface plasmon resonance (SPR) biosensors, and lateral flow assays, demonstrated high sensitivity and specificity in detecting SARSCoV- 2 in clinical samples such as saliva, nasal swabs, and wastewater. Several aptamer structures targeting viral proteins like the spike and nucleocapsid proteins were employed. Nucleic Acid Amplification Techniques (NAATs) utilizing aptamers, such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based and Loop-mediated Isothermal Amplification (LAMP) assays, showed exceptional sensitivity in detecting viral genetic material. Aptamer-based therapeutic approaches showed potential by blocking viral protein activity or serving as delivery vehicles for therapeutic agents like small interfering RNAs (siRNAs). Despite their advantages, aptamer technologies face limitations such as susceptibility to nuclease degradation and rapid renal clearance, highlighting the need for further optimization. Conclusion: Aptamer-based strategies present promising avenues for COVID-19 detection and treatment. These approaches offer advantages such as high sensitivity, specificity, and rapid detection, making them valuable tools in combating the COVID-19 pandemic. Further research and development are warranted to optimize aptamer-based strategies for widespread application in clinical settings.
  • Relationship Between Mycoplasma Pneumoniae Serological Findings and Clinical Outcomes in COVID-19 Patients: A Cross-Sectional Study
    Journal of Mazandaran University of Medical Sciences, 2025
  • Association Between the Level of Vitamin D and COVID-19 Infection in Children and Adolescents: A Systematic Review
    Zohreh-Al-Sadat Ghoreshi, Javad Charostad, Nasir Arefinia, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Aryan Zandi, Seyed Danial Alizadeh, Seyedeh Mahdieh Khoshnazar, Faranak Salajegheh
    American Journal of Tropical Medicine and Hygiene, 2024
  • A Closer Look at the Avian Influenza Virus H7N9: A Calm before the Storm?
    Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Amirhossein Shahpar, Mohammad Pardeshenas, Seyedeh Mahdieh Khoshnazar, Mana Khazaeli, Davood Bashash, Nazanin Zeinali Nezhad, Javad Charostad
    Journal of Medical Virology, 2024
  • Investigation of Liver Function Test Findings in COVID-19 Patients Considering the Disease Timeline
    Mohsen Nakhaie, Javad Charostad, Emad Behboudi, Yaser Ghelmani, Samaneh Jahangiri, Nadieh Baniasadi, Arman Khajouei, Mohammad Reza Zangouey, Faranak Salajegheh
    Jundishapur Journal of Microbiology, 2024
  • Monkeypox (Mpox) vs. Innate immune responses: Insights into evasion mechanisms and potential therapeutic strategies
    Pouya Pashazadeh Azari, Mohammad Rezaei Zadeh Rukerd, Javad Charostad, Davood Bashash, Niloofar Farsiu, Saleh Behzadi, Seyedeh Mahdieh Khoshnazar, Sajjad Heydari, Mohsen Nakhaie
    Cytokine, 2024
  • Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID-19: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials
    Zohreh‐al‐sadat Ghoreshi, Javad Charostad, Nasir Arefinia, Mohsen Nakhaie, Mohammad Rezaei Zadeh Rukerd, Faranak Salajegheh
    Pharmacology Research and Perspectives, 2024
  • Beyond skin deep: shedding light on the neuropsychiatric consequences of Monkeypox (Mpox)
    Mohsen Nakhaie, Zeynab Pirmoradi, Davood Bashash, Mohammad Rezaei Zadeh Rukerd, Javad Charostad
    Acta Neurologica Belgica, 2024
  • From Entry to Evasion: A Comprehensive Analysis of Host-Virus Interactions for Monkeypox
    Vahideh Hamidi Sofiani, Mohammad Rezaei Zadeh Rukerd, Javad Charostad, Mohammad Pardeshenas, Reza Ghazi, Nasir Arefinia, Sara Shafieipour, Faranak Salajegheh, Mohsen Nakhaie
    Infectious Microbes and Diseases, 2024
  • Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis
    Faranak Salajegheh, Mohammad Rezaei Zadeh Rukerd, Mohsen Nakhaie, Zohreh-Al-Sadat Ghoreshi, Javad Charostad, Nasir Arefinia
    Clinical and Experimental Vaccine Research, 2024
  • The Role of Epstein-Barr Virus (EBV) Infected Gastric Cancer in Increasing microRNA124 (miR-124) Promoter Methylation and Enhancer of Zeste Homolog 2 (EZH2) Gene Expression
    Zohreh-Al-Sadat Ghoreshi, Mohammad Rezaei Zadeh Rukerd, Hedyeh Askarpour, Ali Asghar Kheirkhah Vakilabad, M. Nakhaie, M. J. Abbaszadeh Afshar, Emad Behboudi, J. Charostad, Nasir Arefinia
    Medicine United States, 2024
  • JNK Signaling Pathways and Oncoviruses
    Emad Behboudi, Javad Charostad, Mohsen Nakhaie, Arman Khajouei, Yaser Ghelmani
    Iranian Journal of Medical Microbiology, 2024
  • Antiviral activity of Ferula assa-feotida on HSV-1, 2 in vitro
    Javad Charostad, Tahere Navidfar, Masoumeh Kiani, Paul Schinitzler, Akram Astani
    Iranian Journal of Microbiology, 2024
  • Assessment of Torque Teno Virus (TTV) Frequency in Healthy Blood Donors in the Central Region of Iran, Yazd
    Zahra Naderipour, Farzane Behnezhad, Javad Charostad, Mohsen Nakhaie, Nadieh Baniasadi, Yaser Ghelmani, Fateme Akhavan Tafti, Azam Dehghani, Akram Astani
    International Journal of Hematology Oncology and Stem Cell Research, 2024
  • A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep
    Javad Charostad, Mohammad Rezaei Zadeh Rukerd, Shahab Mahmoudvand, Davood Bashash, Seyed Mohammad Ali Hashemi, Mohsen Nakhaie, Keivan Zandi
    Travel Medicine and Infectious Disease, 2023
  • Evaluation of hematological parameters alterations in different waves of COVID-19 pandemic: A cross-sectional study
    Javad Charostad, Mohammad Rezaei Zadeh Rukerd, Azadeh Shahrokhi, Faezeh Afkhami Aghda, Yaser ghelmani, Pouria Pourzand, Sara Pourshaikhali, Shahriar Dabiri, Azam dehghani, Akram Astani, Mohsen Nakhaie, Ehsan Kakavand
    Plos One, 2023
  • Anti-Monkeypox Infection Approaches: From Prevention to Therapeutic Lines
    Somayeh Ghafari, Mohammad Rezaei Zadeh Rukerd, Davood Bashash, Mohsen Nakhaie, Javad Charostad, Mohammad Zarei, Azam Dehghani
    Clinical Pharmacology in Drug Development, 2023
  • Prevalence of Hepatitis C Virus and Its Occult Infection in Hemodialysis Patients
    Mohsen Nakhaie, Ehsan Taheri, Javad Charostad, Nasir Arefinia, Davood Kalantar-Neyestanaki, Mohammad Rezaei Zadeh Rukerd, Fatemeh Ahmadpour, Mohamad Hossein Pourebrahimi, Sara Ahmadinejad Farsangi, Sara Shafieipour
    Jundishapur Journal of Microbiology, 2023
  • Higher Risk of Chronic Hepatitis E Virus Infection in Patients with Human Immunodeficiency Virus-1: An Iranian Cross-sectional Study
    Mohamad Javad Zahedi, Sara Shafieipour, Mohammad Mahdi Hayatbakhsh Abbasi, Nader Pourjamali, Mohsen Nakhaie, Javad Charostad, Mohammad Rezaei Zadeh Rukerd, Mohammad Mehdi Lashkarizadeh, Fatemeh Karami Robati, Azam Dehghani, Yunes Jahani, Seyed Mohamad Ali Arabzadeh, Hamid Reza Mollaei, Ebrahim Ranjbar
    Iranian Journal of Pathology, 2023
  • Monkeypox virus diagnosis and laboratory testing
    Mohsen Nakhaie, Nasir Arefinia, Javad Charostad, Davood Bashash, Mohadeseh Haji Abdolvahab, Mohammad Zarei
    Reviews in Medical Virology, 2023
  • Hepatitis B Virus (HBV) and Occult Hepatitis B Virus (OBI) in Hemodialysis Patients: An Epidemiological Observational Study in Kerman, Iran (2022-2023)
    Mohsen Nakhaie, Sara Ahmadinejad Farsangi, Mohammad Rezaei Zadeh Rukerd, Sara Shafieipour, Nasir Arefinia, Mohammad Javad Zahedi, Shahab Mahmoudvand, Ehsan Taheri, Javad Charostad
    Iranian Journal of Medical Microbiology, 2023
  • Detection of High-Risk Human Papillomavirus DNA in Invasive Ductal Carcinoma Specimens
    Mastaneh Alinezhadi, Manoochehr Makvandi, Gholam Kaydani, Seyed Jazayeri, Javad Charostad, Abdolhassan Talaiezadeh Talaeizadeh, Kambiz Angali
    Asian Pacific Journal of Cancer Prevention, 2022
  • Upregulation of Interleukin-6 in HPV-Positive Breast Cancer Patients
    J. Charostad, A. Azaran, M. Nakhaei, A. Astani, G. Kaydani, A. Motamedfar, M. Makvandi
    Iranian Journal of Immunology, 2021
  • Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the Yazd hospital
    E. Behboudi, V. Hamidi, F. Gholizadeh, E.M. Grala, Y. Ghelmani, M. Nakhaie, J. Charostad, A. Astani
    New Microbes and New Infections, 2021
  • Molecular and Serological Prevalence of HCMV in Iranian Patients with Breast Cancer
    Mohsen Nakhaie, Javad Charostad, Azarakhsh Azaran, Seyyed Ali Mohammad Arabzadeh, Azim Motamedfar, Sara Iranparast, Fatemeh Ahmadpour, Abdolhasan Talaeizadeh, Manoochehr Makvandi
    Asian Pacific Journal of Cancer Prevention, 2021
  • Mirna-218 is frequently downregulated in malignant breast tumors: A footprint of epstein-barr virus infection
    Javad Charostad, Mohsen Nakhaie, Azarakhsh Azaran, Gholam Kaydani, Akram Astani, Azim Motamedfar, Manoochehr Makvandi
    Iranian Journal of Pathology, 2021
  • Prevalence of Human Cytomegalovirus in Breast Cancer: A Systematic Review
    Mohsen Nakhaie, Javad Charostad, Hossein Ghaderi-Zefrehi, Seyyed Ali Mohammad Arabzadeh, Fatemeh Pourhosseini, Manoochehr Makvandi
    Asia Pacific Journal of Cancer Biology, 2021
  • The role of viruses in adenocarcinoma development
    Mohsen Nakhaie, Javad Charostad, Gholam Abbas Kaydani, Ebrahim Faghihloo
    Infection Genetics and Evolution, 2020
  • The interplay between EBV and KSHV viral products and NF-κB pathway in oncogenesis
    J. Charostad, M. Nakhaie, A. Dehghani, E. Faghihloo
    Infectious Agents and Cancer, 2020
  • Downregulation of mir-143/145 cluster in breast carcinoma specimens: Putative role of dna oncoviruses
    Mohsen Nakhaie, Manoochehr Makvandi, Javad Charostad, Seyyed Ali Mohammad Arabzadeh, Azim Motamedfar, Gholam Abbas Kaydani
    Jundishapur Journal of Microbiology, 2020
  • Detection of human herpes viruses 1-5 in miscarriage: A case-control study
    Javad Charostad, Talat Mokhtari-Azad, Jila Yavarian, Nastaran Ghavami, Seyed Mahmood Seyed Khorrami, Emad Behboudi, Somayeh Jalilvand, Somayeh Shatizadeh Malekshahi, Nazanin Zahra Shafiei-Jandaghi
    International Journal of Reproductive Biomedicine, 2020
  • Molecular detection of HHV1-5, AAV and HPV in semen specimens and their impact on male fertility
    Emad Behboudi, Talat Mokhtari-Azad, Jila Yavarian, Nastaran Ghavami, Seyed Mahmood Seyed Khorrami, Farhad Rezaei, Javad Charostad, Somayeh Shatizadeh Malekshahi, Nazanin Zahra Shafiei-Jandaghi
    Human Fertility, 2019
  • DNA methyltransferases in virus-associated cancers
    Javad Charostad, Akram Astani, Hossein Goudarzi, Ebrahim Faghihloo
    Reviews in Medical Virology, 2019

RECENT SCHOLAR PUBLICATIONS

  • An extensive overview on MicroRNAs and pandemic-prone viral diseases: The next frontier in predicting and mitigating pandemics
    N Farsiu, J Charostad, FK Mahani, Y Mir, MRZ Rukerd, NZ Nezhad, ...
    Infection, Genetics and Evolution, 105963 , 2026
    2026
  • From legacy to innovation: A comprehensive review of vaccine platforms against viral infections
    N Farsiu, FK Mahani, N Arefinia, J Charostad, M Pardeshenas, H Mirzaei, ...
    Virus Research, 199730 , 2026
    2026
  • Aptamer‐Based Approaches for Influenza Virus Detection: A Systematic Review
    J Charostad, Z Ghoreshi, N Arefinia, F Salajegheh, N Farsiu, ...
    Health Science Reports 9 (3), e72118 , 2026
    2026
  • Dengue Fever: Viral, Environmental, and Human Factors Driving Expansion and Pandemic Risk
    M Nakhaie, A Shahpar, M Rezaei Zadeh Rukerd, N Farsiu, J Charostad, ...
    Reviews in Medical Virology 36 (1), e70088 , 2026
    2026
    Citations: 7
  • Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue
    N Farsiu, K Zandi, MRZ Rukerd, J Charostad, D Bashash, S Ghafari, ...
    The American journal of tropical medicine and hygiene, tpmd250049 , 2025
    2025
    Citations: 1
  • Prevalence of Torque Teno Virus in Thalassemia Patients in Yazd City
    J Charostad, M Abdollahi, FA Tafti, N Taghavi, HJZ Shahshahani, ...
    International Journal of Medical Laboratory , 2025
    2025
  • Aptamer-based Strategies for COVID-19 Detection and Treatment: A Systematic Review Study
    M Nakhaie, ZAS Ghoreshi, J Charostad, F Salajegheh, MRZ Rukerd, ...
    Current Analytical Chemistry 21 (6), 635-651 , 2025
    2025
    Citations: 1
  • The safety and efficacy of remdesivir-dexamethasone combination therapy versus dexamethasone monotherapy in COVID-19: A rapid review and meta-analysis
    M Nakhaie, F Salajegheh, N Arefinia, M Rezaei Zadeh Rukerd, ...
    Archives of Razi Institute , 2025
    2025
  • Evaluating the role of COVID-19 vaccines in patient outcomes: evidence from the eighth wave in Kerman, Iran
    FR Sarbijan, N Farsiu, S Shafieipour, H Abousaidi, R Sinaei, A Amirbeigi, ...
    Infectious Diseases in Clinical Practice 33 (2), e1433 , 2025
    2025
    Citations: 3
  • Mpox and Viral Co‐Infections: A Narrative Review
    M Nakhaie, MRZ Rukerd, N Farsiu, D Bashash, FK Mahani, N Arefinia, ...
    Health Science Reports 8 (2), e70464 , 2025
    2025
    Citations: 7
  • Relationship Between Mycoplasma Pneumoniae Serological Findings and Clinical Outcomes in COVID-19 Patients: A Cross-Sectional Study
    M Nakhaie, S Nakhaie, N Farsiu, R Sinaei, J Charostad, S Torabian, ...
    Journal of Mazandaran University of Medical Sciences 34 (241), 79-88 , 2025
    2025
  • EVALUATING THE ROLE OF COVID-19 VACCINES IN PATIENT OUTCOMES
    SF RAISI, N FARSIU, S SHAFIEIPOUR, H ABOUSAIDI, R SINAEI, ...
    INFECTIOUS DISEASES IN CLINICAL PRACTICE 33 (2) , 2025
    2025
  • Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications
    M Golban, J Charostad, H Kazemian, H Heidari
    Infectious Diseases and Therapy 14 (1), 13-57 , 2025
    2025
    Citations: 52
  • Antiviral activity of Ferula assa-feotida on HSV-1, 2 in vitro
    J Charostad, T Navidfar, M Kiani, P Schinitzler, A Astani
    Iranian Journal of Microbiology 16 (6), 786 , 2024
    2024
    Citations: 3
  • Investigation of liver function test findings in COVID-19 patients considering the disease timeline
    M Nakhaie, J Charostad, E Behboudi, Y Ghelmani, S Jahangiri, ...
    Jundishapur Journal of Microbiology 17 (11), 1-10 , 2024
    2024
    Citations: 2
  • A closer look at the avian influenza virus H7N9: a calm before the storm?
    M Nakhaie, MRZ Rukerd, A Shahpar, M Pardeshenas, SM Khoshnazar, ...
    Journal of medical virology 96 (11), e70090 , 2024
    2024
    Citations: 6
  • Monkeypox (Mpox) vs. Innate immune responses: Insights into evasion mechanisms and potential therapeutic strategies
    PP Azari, MRZ Rukerd, J Charostad, D Bashash, N Farsiu, S Behzadi, ...
    Cytokine 183, 156751 , 2024
    2024
    Citations: 16
  • Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID‐19: A GRADE‐assessed systematic review and meta‐analysis of randomized controlled trials
    Z Ghoreshi, J Charostad, N Arefinia, M Nakhaie, M Rezaei Zadeh Rukerd, ...
    Pharmacology Research & Perspectives 12 (5), e70013 , 2024
    2024
    Citations: 6
  • Effect of vitamin D supplementation on clinical outcomes in adult patients with COVID‐19: A GRADE‐assessed systematic review and meta‐analysis of randomized controlled trials
    J Charostad, N Arefinia, M Nakhaie, MRZ Rukerd, F Salajegheh
    Pharmacology Research & Perspectives 12 (5), e70013 , 2024
    2024
  • Association between the level of vitamin D and COVID-19 infection in children and adolescents: a systematic review
    J Charostad, N Arefinia, M Nakhaie, MRZ Rukerd, A Zandi, SD Alizadeh, ...
    The American Journal of Tropical Medicine and Hygiene 111 (5), 1127 , 2024
    2024
    Citations: 2

MOST CITED SCHOLAR PUBLICATIONS

  • A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep
    J Charostad, MRZ Rukerd, S Mahmoudvand, D Bashash, SMA Hashemi, ...
    Travel medicine and infectious disease 55, 102638 , 2023
    2023
    Citations: 271
  • Monkeypox virus diagnosis and laboratory testing
    M Nakhaie, N Arefinia, J Charostad, D Bashash, M Haji Abdolvahab, ...
    Reviews in medical virology 33 (1), e2404 , 2023
    2023
    Citations: 62
  • An overview of history, evolution, and manufacturing of various generations of vaccines
    A Tahamtan, J Charostad, SSJ HOSEINI, M Barati
    Journal of Archives in Military Medicine 5 (3), 0-0 , 2017
    2017
    Citations: 61
  • Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications
    M Golban, J Charostad, H Kazemian, H Heidari
    Infectious Diseases and Therapy 14 (1), 13-57 , 2025
    2025
    Citations: 52
  • Association between ABO blood groups and rhesus antigen and susceptibility to COVID-19 in the Yazd hospital
    E Behboudi, V Hamidi, F Gholizadeh, EM Grala, Y Ghelmani, M Nakhaie, ...
    New Microbes and New infections 44, 100934 , 2021
    2021
    Citations: 38
  • The interplay between EBV and KSHV viral products and NF-κB pathway in oncogenesis
    J Charostad, M Nakhaie, A Dehghani, E Faghihloo
    Infectious Agents and Cancer 15 (1), 62 , 2020
    2020
    Citations: 36
  • DNA methyltransferases in virus‐associated cancers
    J Charostad, A Astani, H Goudarzi, E Faghihloo
    Reviews in medical virology 29 (2), e2022 , 2019
    2019
    Citations: 32
  • Role of lifestyle medicine in the prevention and treatment of diseases
    M Farrokhi, F Taheri, Z Bayat, M Damiri, M Farrokhi, E Ghadirzadeh, ...
    Amazon Kindle Direct Publishing , 2024
    2024
    Citations: 29
  • Molecular detection of HHV1-5, AAV and HPV in semen specimens and their impact on male fertility
    E Behboudi, T Mokhtari-Azad, J Yavarian, N Ghavami, ...
    Human Fertility 22 (2), 133-138 , 2019
    2019
    Citations: 22
  • From entry to evasion: a comprehensive analysis of host-virus interactions for Monkeypox
    VH Sofiani, MRZ Rukerd, J Charostad, M Pardeshenas, R Ghazi, ...
    Infectious Microbes & Diseases 6 (2), 56-64 , 2024
    2024
    Citations: 17
  • Detection of human herpes viruses 1-5 in miscarriage: A case-control study
    J Charostad, T Mokhtari-Azad, J Yavarian, N Ghavami, SMS Khorrami, ...
    International Journal of Reproductive BioMedicine 18 (7), 501 , 2020
    2020
    Citations: 17
  • Monkeypox (Mpox) vs. Innate immune responses: Insights into evasion mechanisms and potential therapeutic strategies
    PP Azari, MRZ Rukerd, J Charostad, D Bashash, N Farsiu, S Behzadi, ...
    Cytokine 183, 156751 , 2024
    2024
    Citations: 16
  • Upregulation of interleukin-6 in HPV-positive breast cancer patients
    J Charostad, A Azaran, M Nakhaei, A Astani, GA Kaydani, A Motamedfar, ...
    Iranian Journal of Immunology 18 (4), 315-330 , 2021
    2021
    Citations: 15
  • The role of viruses in adenocarcinoma development
    M Nakhaie, J Charostad, GA Kaydani, E Faghihloo
    Infection, Genetics and Evolution 86, 104603 , 2020
    2020
    Citations: 15
  • Detection of high-risk human papillomavirus DNA in invasive ductal carcinoma specimens
    M Alinezhadi, M Makvandi, GA Kaydani, SN Jazayeri, J Charostad, ...
    Asian Pacific journal of cancer prevention: APJCP 23 (9), 3201 , 2022
    2022
    Citations: 13
  • Evaluation of hematological parameters alterations in different waves of COVID-19 pandemic: A cross-sectional study
    J Charostad, M Rezaei Zadeh Rukerd, A Shahrokhi, FA Aghda, ...
    Plos one 18 (8), e0290242 , 2023
    2023
    Citations: 11
  • Molecular and serological prevalence of HCMV in Iranian patients with breast cancer
    M Nakhaie, J Charostad, A Azaran, SAM Arabzadeh, A Motamedfar, ...
    Asian Pacific journal of cancer prevention: APJCP 22 (7), 2011 , 2021
    2021
    Citations: 10
  • JNK signaling pathways and oncoviruses
    E Behboudi, J Charostad, M Nakhaie, A Khajouei, Y Ghelmani
    Iranian Journal of Medical Microbiology 18 (3), 148-162 , 2024
    2024
    Citations: 9
  • Beyond skin deep: shedding light on the neuropsychiatric consequences of Monkeypox (Mpox)
    M Nakhaie, Z Pirmoradi, D Bashash, MRZ Rukerd, J Charostad
    Acta Neurologica Belgica 124 (4), 1189-1197 , 2024
    2024
    Citations: 8
  • Rezaei Zadeh Rukerd M, Shahrokhi A, Aghda FA, ghelmani Y, Pourzand P, et al.(2023) Evaluation of hematological parameters alterations in different waves of COVID-19 pandemic: A …
    J Charostad
    Plos one 18 (8), e0290242 , 2023
    2023
    Citations: 8